Switch to:
Also traded in: Canada

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TBUFF's 30-Y Financials

Financials (Next Earnings Date: 0)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with TBUFF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic  
Compare:TSX:CPH, NAS:ARLZ, TSXV:RX, TSXV:EMC, TSX:MSL, TSXV:THCX, TSX:CMED, TSXV:OGI, XCNQ:MDM, TSX:NRI, TSXV:MGW, TSXV:WMD, XCNQ:IN, XCNQ:GLH, XCNQ:EAT, TSX:ASP, XCNQ:MJ, XCNQ:BCC, TSXV:AQS, TSX:EPI » details
Traded in other countries:TRX.Canada,
Headquarter Location:Canada
Tribute Pharmaceuticals Canada Inc is a Canadian specialty pharmaceutical company engaged in the acquisition, licensing, development and promotion of healthcare products in the Canadian and U.S. markets.

Tribute Pharmaceuticals Canada Inc was incorporated under the Business Corporations Act (Ontario) on November 14, 1994. The Company is a specialty pharmaceutical company. It conducts acquisition, licensing, development and promotion of healthcare products in Canada. It sells Uracyst and NeoVisc internationally through a number of strategic partnerships. The Company's portfolio of assets includes nine product lines, eight of which are on the market in Canada, including: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, Collatamp G, and MycoVa. The Company markets its products in Canada through its own sales force and currently has licensing agreements for the distribution of select products in over 20 countries, and continues to expand this footprint. It faces product competition from companies marketing competing pharmaceutical products and medical devices in Canada. The Company's operations are or may be subject to various federal, provincial, state and local laws, regulations and recommendations relating to the marketing of products and relationships with treating physicians, data protection, safe working conditions, laboratory and manufacturing practices, the export of products to certain countries and the purchase, storage, movement, use and disposal of hazardous or potentially hazardous substances.

Ratios

vs
industry
vs
history

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue (TTM) (Mil) $21.16
EPS (TTM) $ -0.11
Short Percentage of Float0.71%
52-Week Range $0.50 - 1.86
Shares Outstanding (Mil)126.24

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue (Mil $) 23 30 38 41
EPS ($) -0.07 0.02 0.08 0.04
EPS without NRI ($) -0.07 0.02 0.08 0.04
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for TBUFF

Headlines

Articles On GuruFocus.com
Tribute Announces Results of Shareholder Vote Feb 01 2016 
Leading Independent Advisors Recommend That Tribute Shareholders Vote FOR the Transaction Jan 21 2016 
Tribute Pharmaceuticals Receives Notice of Allowance for Canadian Patent Expanding Cambia(R) Use in Jan 04 2016 
RETRANSMISSION: Tribute Schedules Special Shareholder Meeting for February 1, 2016 Dec 29 2015 
Tribute Schedules Special Shareholder Meeting for February 1, 2016 Dec 28 2015 
POZEN and Tribute Announce Plan to Proceed With Merger to Form Aralez Pharmaceuticals Dec 07 2015 
Tribute Comments on Trading Activity at the Request of IIROC Sep 29 2015 
Tribute Pharmaceuticals to Present at the Bloom Burton & Co. Annual Healthcare Investor Conference Apr 27 2015 
Tribute Pharmaceuticals Provides Update of 2014 Revenues; Anticipates Fourth Quarter Revenue Growth Jan 27 2015 
CORRECTION FROM SOURCE: Tribute Pharmaceuticals Schedules Third Quarter 2014 Financial Results Confe Nov 03 2014 

More From Other Websites
ARLZ: NDA for YOSPRALA® Submitted; Approval Likely in the Fourth Quarter of 2016… Mar 22 2016
ARLZ: A Strong Management Team and Plenty of Capital Makes Aralez a Top Specialty Pharmaceutical... Feb 26 2016
Tribute Announces Results of Shareholder Vote Feb 01 2016
Leading Independent Advisors Recommend That Tribute Shareholders Vote FOR the Transaction Jan 21 2016
Tribute Mails Materials in Connection With Special Meeting of Shareholders to Approve Transaction... Jan 11 2016
Tribute Pharmaceuticals Receives Notice of Allowance for Canadian Patent Expanding Cambia(R) Use in... Jan 04 2016
POZN: Shareholder Meetings Set for Early February; YOSPRALA® NDA to be re-filed in 2Q16 Dec 29 2015
RETRANSMISSION: Tribute Schedules Special Shareholder Meeting for February 1, 2016 Dec 29 2015
Tribute Pharmaceuticals Canada, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 21 2015
POZEN and Tribute Announce Plan to Proceed With Merger to Form Aralez Pharmaceuticals Dec 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}